# A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)

> **NCT01358331** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 25 (actual)

## Conditions studied

- Tumor, Solid

## Interventions

- **DRUG:** MK-8353

## Key facts

- **NCT ID:** NCT01358331
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11-04
- **Primary completion:** 2014-05-20
- **Final completion:** 2014-05-20
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01358331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01358331, "A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01358331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*